

**STERLING BIOTECH LIMITED**

Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2011

(Rs. in Lacs)

Sr. No.	Particulars	Quarter ended 30/09/2011	Corresponding Quarter ended 30/09/2010	Nine Months ended 30/09/2011	Corresponding Nine Months ended 30/09/2010	Twelve Months ended 31/12/2010
		Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income					
	a) Net Sales/Income from Operations	45,104.29	40,978.47	133,537.61	118,854.94	161,657.85
	b) Other Operating Income	226.38	316.84	746.44	725.57	1,063.76
	<b>c) Total</b>	<b>45,330.67</b>	<b>41,295.31</b>	<b>134,284.05</b>	<b>119,580.51</b>	<b>162,721.61</b>
2	Expenditure					
	a) (Increase)/decrease in stock in trade and work in progress	1,258.41	(709.25)	(3,843.51)	(9,128.09)	(9,332.32)
	b) Consumption of raw materials	25,022.59	20,093.31	67,661.93	68,545.76	89,387.90
	c) Employees Cost	1,327.73	1,138.96	3,723.69	3,348.82	4,371.50
	d) Depreciation	6,143.40	5,313.28	18,931.22	12,579.09	19,762.17
	e) Other expenditure	2,671.39	1,904.92	12,538.70	5,573.89	7,522.53
	<b>f) Total</b>	<b>36,423.52</b>	<b>27,741.22</b>	<b>99,012.03</b>	<b>80,919.47</b>	<b>111,711.78</b>
3	Profit / (Loss) from Operations before Other Income and Interest (1-2)	8,907.15	13,554.09	35,272.02	38,661.04	51,009.83
4	Other Income	0.00	0.00	0.00	0.00	0.00
5	Profit / (Loss) before Interest (3+4)	8,907.15	13,554.09	35,272.02	38,661.04	51,009.83
6	Interest	7,184.38	6,082.76	19,775.96	16,828.73	23,047.05
7	<b>Profit / (Loss) from Ordinary Activities before tax (5-6)</b>	<b>1,722.77</b>	<b>7,471.33</b>	<b>15,496.06</b>	<b>21,832.31</b>	<b>27,962.78</b>
8	Tax expense					
	a) Current	320.18	900.00	2,815.85	3,470.00	4,020.00
	b) Deferred	208.12	500.00	1,916.30	2,650.00	3,100.00
	c) Fringe Benefit	0.00	0.00	0.00	0.00	0.00
	<b>d) Total</b>	<b>528.30</b>	<b>1,400.00</b>	<b>4,732.15</b>	<b>6,120.00</b>	<b>7,120.00</b>
9	<b>Net Profit / (Loss) from Ordinary Activities after tax (7-8)</b>	<b>1,194.47</b>	<b>6,071.33</b>	<b>10,763.91</b>	<b>15,712.31</b>	<b>20,842.78</b>
10	Extraordinary Items	(121.87)	(3,008.12)	(1,427.55)	(3,474.48)	(6,310.48)
11	<b>Net Profit / (Loss) for the period (9-10)</b>	<b>1,072.60</b>	<b>3,063.21</b>	<b>9,336.36</b>	<b>12,237.83</b>	<b>14,532.30</b>
12	Prior year adjustment	0.00	0.00	0.00	0.00	88.39
13	<b>Profit available for appropriation</b>	<b>1,072.60</b>	<b>3,063.21</b>	<b>9,336.36</b>	<b>12,237.83</b>	<b>14,620.69</b>
14	Paid-up equity share capital (Face Value of Re.1/- per share)	2,678.74	2,678.74	2,678.74	2,678.74	2,678.74
15	Reserves excluding Revaluation Reserves as per balance sheet.					244,415.28
16	Earnings Per Share (EPS)					
	a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) on F.V. of Re.1/- per share.					
	Basic	0.45	2.38	4.02	6.16	8.16
	Diluted	0.39	2.01	3.56	5.19	7.19
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) on F.V. of Re.1/- per share.					
	Basic	0.40	1.20	3.49	4.79	5.69
	Diluted	0.35	1.01	3.09	4.05	5.01
17	Public Shareholding					
	- Number of shares	133,240,656	133,666,531	133,240,656	133,666,531	133,666,531
	- Percentage of shareholding	49.74%	49.90%	49.74%	49.90%	49.90%

**STERLING BIOTECH LIMITED**

Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021

**UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2011**

(Rs. in Lacs)

Sr. No.	Particulars	Quarter ended 30/09/2011	Corresponding Quarter ended 30/09/2010	Nine Months ended 30/09/2011	Corresponding Nine Months ended 30/09/2010	Twelve Months ended 31/12/2010
		Unaudited	Unaudited	Unaudited	Unaudited	Audited
18	Promoters and Promoter Group Shareholding					
	a) Pledged/Encumbered					
	Number of shares	75,777,817	30,527,000	75,777,817	30,527,000	18,228,340
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	84.71%	34.29%	84.71%	34.29%	20.47%
	Percentage of shares (as a % of the total share capital of the Company)	28.29%	11.40%	28.29%	11.40%	6.80%
	b) Non-encumbered					
	Number of shares	13,682,752	58,507,694	13,682,752	58,507,694	70,806,354
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	15.29%	65.71%	15.29%	65.71%	79.53%
	Percentage of shares (as a % of the total share capital of the Company)	5.11%	21.84%	5.11%	21.84%	26.43%

**Notes:**

- The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.
- The above Financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors in its meeting held on 14 November 2011.
- The Statutory Auditors have carried out a limited review of the financial results for the quarter ended 30 September 2011.
- The Company has formed Overseas Subsidiary namely Sterling Fincom Pvt. Ltd., Mauritius and there are no business operations in the said subsidiary company.
- The number of investor complaints for the quarter ended on 30 September 2011 were :  
Opening - NIL, Received - 22, Disposed off - 22, and Balance - NIL.
- Previous period figures have been regrouped/reclassified, wherever necessary.

**For and on Behalf of  
STERLING BIOTECH LIMITED**

Place : Mumbai  
Date : 14 November 2011.

**Chetan J. Sandesara  
Joint Managing Director**